Teva Statement on European Commission Decision; Company to Appeal

31.10.24 12:29 Uhr

Werte in diesem Artikel

  • Teva Pharmaceuticals disagrees with the European Commission decision, which is based on legal theories that the company believes are extreme, untested, and factually unsupported
  • The company intends to appeal the outcome and is fully prepared to mount its defense
  • Teva has supported the MS community since 1996 and will not be distracted from providing access to this important standard-of-care treatment
  • Teva works to the highest ethical standards with all our external experts and do so in a highly regulated environment

TEL AVIV, Israel, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals Industries Ltd. (NYSE: and TASE: TEVA) is responding to the European Decision following its investigation into the company’s practices regarding COPAXONE® -- the standard-of-care treatment for multiple sclerosis – and announcing its intention to appeal the judgement and fine imposed.

The company is deeply disappointed by this decision and has been cooperating extensively with the EC since 2019. Teva disagrees with the Commission’s legal theories which are legally untested and, Teva believes, not supported by the facts. The company will vigorously defend its position on appeal and is well prepared financially to mount a defense.

Teva conducts its business lawfully and ethically and has been a strong partner to Europe, its patients, economy and healthcare systems. This misguided decision will not distract Teva from its unwavering support for patients living with MS and their families.

Media Contacts:

Kelley Dougherty (973) 832-2810

Eden Klein +972 (3) 906 2645   


Ausgewählte Hebelprodukte auf Teva Pharmaceutical Industries

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Teva Pharmaceutical Industries

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Teva Pharmaceutical Industries Ltd. (spons. ADRs)

Analysen zu Teva Pharmaceutical Industries Ltd. (spons. ADRs)

DatumRatingAnalyst
19.07.2019Teva Pharmaceutical Industries Peer PerformWolfe Research
11.06.2019Teva Pharmaceutical Industries UnderweightBarclays Capital
03.06.2019Teva Pharmaceutical Industries OutperformOppenheimer & Co. Inc.
29.03.2019Teva Pharmaceutical Industries Market PerformBMO Capital Markets
21.09.2018Teva Pharmaceutical Industries PerformOppenheimer & Co. Inc.
DatumRatingAnalyst
03.06.2019Teva Pharmaceutical Industries OutperformOppenheimer & Co. Inc.
29.03.2019Teva Pharmaceutical Industries Market PerformBMO Capital Markets
09.01.2018Teva Pharmaceutical Industries BuyMizuho
11.09.2017Teva Pharmaceutical Industries BuyBTIG Research
17.07.2017Teva Pharmaceutical Industries OutperformRBC Capital Markets
DatumRatingAnalyst
19.07.2019Teva Pharmaceutical Industries Peer PerformWolfe Research
21.09.2018Teva Pharmaceutical Industries PerformOppenheimer & Co. Inc.
17.09.2018Teva Pharmaceutical Industries NeutralBTIG Research
09.02.2018Teva Pharmaceutical Industries HoldGabelli & Co
09.02.2018Teva Pharmaceutical Industries Sector PerformRBC Capital Markets
DatumRatingAnalyst
11.06.2019Teva Pharmaceutical Industries UnderweightBarclays Capital
02.02.2018Teva Pharmaceutical Industries SellBTIG Research
03.11.2017Teva Pharmaceutical Industries UnderperformRBC Capital Markets
30.10.2017Teva Pharmaceutical Industries UnderperformRBC Capital Markets
18.09.2017Teva Pharmaceutical Industries UnderperformRBC Capital Markets

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Teva Pharmaceutical Industries Ltd. (spons. ADRs) nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"